• Company
• Ajovy will it be possible to register this year?
• by Eo, Yun-Ho Dec 1, 2022 05:46am

• Company
• Expansion of Roche Polivy's indication of primary therapy
• by Eo, Yun-Ho Dec 1, 2022 05:46am

• Policy
• Roche’s Lunsumio receives 1st GIFT designation in Korea
• by Lee, Hye-Kyung Dec 1, 2022 05:46am

• Policy
• The price of Donepezil 5mg fell below 500 won
• by Lee, Tak-Sun Dec 1, 2022 05:46am

• Policy
• Pediatric drugs eligible for PE exemptions from January
• by Kim, Jung-Ju Dec 1, 2022 05:46am

• Company
• When will Xocova be approved in Korea?
• by Nho, Byung Chul Nov 30, 2022 05:53am

• Company
• Doveprella, the first new tuberculosis drug in 50 years,
• by Eo, Yun-Ho Nov 30, 2022 05:52am

• Company
• Oluminant's sales are higher than Xeljanz's
• by Kim, Jin-Gu Nov 30, 2022 05:52am

• Company
• Boryung, start patent challenge for liver cancer drug Lenvim
• by Kim, Jin-Gu Nov 30, 2022 05:52am

• Company
• Samsung Bioepis occupies 25% of Avastin mkt 1yr since launch
• by Nov 30, 2022 05:52am